We expect to open up to 30 sites for the Phase 2 stage of the clinical trial. We anticipate all sites will be activated by the end of 2021. We implemented a number of measures to ensure employee safety and business continuity. Our office and general and administrative team continues to work predominantly from home. We believe the effects of the COVID-19 pandemic or its impact contributed to such delays. There are three key elements to our safety strategy. Following administration of compounds, mouse survival and body weights were recorded. The biodistribution of the SNAs was followed for 14 days by PET/CT scans. Any patents that may issue from these applications would expire by 2035. We have the right to sublicense these rights to third parties. Some nonclinical testing may continue even after the IND is submitted. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. 35Table of ContentsPediatric exclusivity and pediatric use. These laws may impact, among other things, our proposed sales and marketing strategies. We consider our relations with our employees to be good. 45Table of ContentsItem 1A. Risk Factors. We have had significant operating losses since our inception. As of December 31, 2020, we have generated an accumulated deficit of $124.8 million. The amount of future losses is uncertain. We expect our operating results to be subject to quarterly fluctuations. In addition, numerous compounds are in clinical development for psoriasis treatment. We currently have no sales, marketing or distribution capabilities or experience. 8226;We will develop additional proprietary technologies that are patentable. 8226;The patents of others will not have an adverse effect on our business. Oligonucleotide and SNA-based therapeutics are a relatively new scientific field.